Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price ...

Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles Soria, senior vice president of oncology within global ...

U.S. Bancorp Dep. Pfd. (Rep. 1/1000th Non-Cum. Perp. Pfd. Series K) 1.15% U.S. Bancorp Dep. Pfd. (Rep. 1/1000th Perp. 3.75% Pfd. Series L) 0.86% U.S. Bancorp Dep. Pfd ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...